AI-ACCELERATED DRUG DISCOVERY

Radial spoke head protein 3 homolog

Explore its Potential with AI-Driven Innovation
Predicted by Alphafold

Radial spoke head protein 3 homolog - Focused Library Design

Available from Reaxense

This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Radial spoke head protein 3 homolog including:

1. LLM-powered literature research

Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Radial spoke head protein 3 homolog therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.

 Fig. 1. Preliminary target research workflow

2. AI-Driven Conformational Ensemble Generation

Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Radial spoke head protein 3 homolog, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.

 Fig. 2. AI-powered molecular dynamics simulations workflow

3. Binding pockets identification and characterization

We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.

 Fig. 3. AI-based binding pocket detection workflow

4. AI-Powered Virtual Screening

Our ecosystem is equipped to perform AI-driven virtual screening on Radial spoke head protein 3 homolog. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Radial spoke head protein 3 homolog. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.

 Fig. 4. The screening workflow of Receptor.AI

Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.

The focused library for Radial spoke head protein 3 homolog includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Radial spoke head protein 3 homolog

partner:

Reaxense

upacc:

Q86UC2

UPID:

RSPH3_HUMAN

Alternative names:

A-kinase anchor protein RSPH3; Radial spoke head-like protein 2

Alternative UPACC:

Q86UC2; Q96LQ5; Q96LX2; Q9BX75

Background:

Radial spoke head protein 3 homolog (RSPH3) is pivotal in the motility of sperm and cilia, functioning within axonemal radial spoke complexes. It acts as a scaffold for the cAMP-dependent protein kinase holoenzyme, integrating MAPK and PKA signaling pathways in cilia.

Therapeutic significance:

RSPH3's mutation leads to primary ciliary dyskinesia, 32, marked by chronic respiratory infections and bronchiectasis due to motile cilia abnormalities. Targeting RSPH3 could revolutionize treatments for respiratory diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.